UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2752) 2752
Book Chapter (65) 65
Newspaper Article (18) 18
Newsletter (16) 16
Magazine Article (15) 15
Poster (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2210) 2210
dabigatran (2015) 2015
science & technology (1982) 1982
life sciences & biomedicine (1949) 1949
anticoagulants (1122) 1122
rivaroxaban (1026) 1026
administration, oral (986) 986
male (918) 918
atrial fibrillation (871) 871
anticoagulants - therapeutic use (856) 856
female (841) 841
aged (808) 808
anticoagulants - administration & dosage (808) 808
cardiovascular system & cardiology (808) 808
atrial fibrillation - drug therapy (752) 752
beta-alanine - analogs & derivatives (732) 732
anticoagulants - adverse effects (708) 708
warfarin (604) 604
stroke (589) 589
stroke - prevention & control (586) 586
apixaban (575) 575
hemorrhage - chemically induced (549) 549
benzimidazoles - therapeutic use (545) 545
middle aged (533) 533
benzimidazoles - administration & dosage (522) 522
atrial fibrillation - complications (488) 488
dabigatran etexilate (487) 487
cardiac & cardiovascular systems (481) 481
benzimidazoles - adverse effects (475) 475
treatment outcome (464) 464
hematology (437) 437
dabigatran - administration & dosage (432) 432
peripheral vascular disease (430) 430
risk factors (430) 430
aged, 80 and over (421) 421
dabigatran - adverse effects (396) 396
pyridones - therapeutic use (387) 387
pyrazoles - therapeutic use (386) 386
dabigatran - therapeutic use (377) 377
antithrombins - adverse effects (373) 373
pharmacology & pharmacy (370) 370
warfarin - therapeutic use (370) 370
antithrombins - administration & dosage (360) 360
beta-alanine - therapeutic use (360) 360
thromboembolism (359) 359
beta-alanine - administration & dosage (350) 350
thrombin (345) 345
general & internal medicine (340) 340
beta-alanine - adverse effects (338) 338
drug therapy (327) 327
abridged index medicus (321) 321
stroke - etiology (316) 316
pyrazoles - administration & dosage (314) 314
pyridones - administration & dosage (314) 314
medicine, general & internal (311) 311
antithrombins - therapeutic use (297) 297
pyridines - therapeutic use (289) 289
dosage and administration (288) 288
cardiac arrhythmia (287) 287
warfarin - adverse effects (281) 281
warfarin - administration & dosage (265) 265
bleeding (264) 264
care and treatment (264) 264
medicine & public health (263) 263
pyridines - administration & dosage (262) 262
morpholines - therapeutic use (260) 260
prevention (260) 260
thiophenes - therapeutic use (260) 260
blood coagulation - drug effects (257) 257
pyrazoles - adverse effects (239) 239
pyridones - adverse effects (239) 239
analysis (238) 238
rivaroxaban - therapeutic use (230) 230
anticoagulation (223) 223
hemorrhage (222) 222
rivaroxaban - administration & dosage (216) 216
patients (215) 215
retrospective studies (208) 208
pyridines - adverse effects (205) 205
venous thromboembolism - prevention & control (205) 205
adult (196) 196
edoxaban (194) 194
cardiology (190) 190
venous thromboembolism (190) 190
thromboembolism - prevention & control (188) 188
anticoagulants - pharmacology (187) 187
vitamin k - antagonists & inhibitors (186) 186
morpholines - administration & dosage (185) 185
thiophenes - administration & dosage (185) 185
thrombosis (183) 183
risk assessment (179) 179
internal medicine (177) 177
rivaroxaban - adverse effects (177) 177
dose-response relationship, drug (175) 175
randomized controlled trials as topic (174) 174
research (168) 168
animals (166) 166
venous thromboembolism - drug therapy (166) 166
anticoagulants - pharmacokinetics (162) 162
cardiovascular (162) 162
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2696) 2696
German (69) 69
French (54) 54
Russian (42) 42
Spanish (37) 37
Japanese (20) 20
Hungarian (11) 11
Danish (8) 8
Italian (7) 7
Swedish (7) 7
Czech (5) 5
Turkish (5) 5
Dutch (4) 4
Portuguese (4) 4
Norwegian (3) 3
Polish (3) 3
Arabic (1) 1
Finnish (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of thrombosis and haemostasis, ISSN 1538-7933, 09/2018, Volume 16, Issue 9, pp. 1891 - 1894
Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Recurrence | Pulmonary Embolism - prevention & control | Pyrazoles - therapeutic use | Dabigatran - administration & dosage | Prospective Studies | Anticoagulants - administration & dosage | Humans | Thiazoles - administration & dosage | Antithrombins - administration & dosage | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Rivaroxaban - administration & dosage | Venous Thromboembolism - drug therapy | Factor Xa Inhibitors - administration & dosage | Neoplasms - complications | Pyridones - administration & dosage | Venous Thromboembolism - prevention & control | Multicenter Studies as Topic | Neoplasms - blood | Dalteparin - therapeutic use | Observational Studies as Topic | Venous Thrombosis - prevention & control | Rivaroxaban - therapeutic use | Pyridines - therapeutic use | Pyridines - administration & dosage | Venous Thrombosis - drug therapy | Administration, Oral | Antithrombins - therapeutic use | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Venous Thrombosis - etiology | Randomized Controlled Trials as Topic | Venous Thromboembolism - etiology | Factor Xa Inhibitors - therapeutic use | Pyrazoles - administration & dosage | Patient Acceptance of Health Care | Pulmonary Embolism - etiology | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Pulmonary Embolism - drug therapy | Pyridones - therapeutic use | Hemorrhage - chemically induced | Care and treatment | Anticoagulants (Medicine) | Thromboembolism | Drug therapy | Cancer | Anticoagulants | Index Medicus
Journal Article
Thrombosis and haemostasis, ISSN 0340-6245, 04/2011, Volume 105, Issue 4, pp. 721 - 729
This trial compared the efficacy and safety of oral dabigatran, a direct thrombin inhibitor, versus subcutaneous enoxaparin for extended thromboprophylaxis in... 
Dabigatran etexilate | Oral anticoagulant | Total hip arthroplasty | Venous thromboembolism | Prophylaxis | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Venous Thromboembolism - mortality | Anticoagulants - administration & dosage | Humans | Middle Aged | Male | Antithrombins - administration & dosage | Dabigatran | Enoxaparin - adverse effects | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Benzimidazoles - administration & dosage | Hemorrhage - etiology | Injections, Subcutaneous | Female | Venous Thrombosis - prevention & control | Benzimidazoles - adverse effects | beta-Alanine - analogs & derivatives | Postoperative Complications | beta-Alanine - adverse effects | Double-Blind Method | Administration, Oral | Venous Thrombosis - mortality | beta-Alanine - administration & dosage | Anticoagulants - adverse effects | Venous Thrombosis - etiology | Venous Thromboembolism - etiology | Antithrombins - adverse effects | Survival Analysis | Arthroplasty, Replacement, Hip - mortality | Aged | Benzimidazoles | Venous Thrombosis | Oral | Hemorrhage | Antithrombins | Venous Thromboembolism | administration & dosage | Surgery | beta-Alanine | Administration | Anticoagulants | Subcutaneous | Enoxaparin | Arthroplasty | Replacement | prevention & control | Kirurgi | Hip | etiology | Injections | analogs & derivatives | adverse effects | mortality
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 04/2014, Volume 111, Issue 4, pp. 575 - 582
Journal Article
Stroke (1970), ISSN 1524-4628, 06/2013, Volume 44, Issue 6, pp. 1676 - 1681
Background and Purpose-To estimate the cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrillation by using novel oral... 
Intracranial hemorrhage | Stroke | Anticoagulation | Markov model | Cost-effectiveness | Atrial fibrillation | Clinical Neurology | Peripheral Vascular Disease | Neurosciences & Neurology | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Thiophenes - therapeutic use | Markov Chains | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | United States | Humans | Anticoagulants - economics | Thiophenes - administration & dosage | Warfarin - economics | Benzimidazoles - economics | Dabigatran | Morpholines - economics | Warfarin - administration & dosage | Warfarin - therapeutic use | Dose-Response Relationship, Drug | Pyridones - administration & dosage | Rivaroxaban | Benzimidazoles - administration & dosage | beta-Alanine - economics | Stroke - epidemiology | Thiophenes - economics | Pyridones - economics | beta-Alanine - analogs & derivatives | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Quality-Adjusted Life Years | Stroke - prevention & control | Administration, Oral | Morpholines - administration & dosage | Risk Factors | Atrial Fibrillation - complications | beta-Alanine - administration & dosage | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Models, Statistical | Pyrazoles - economics | Pyrazoles - administration & dosage | Cost-Benefit Analysis | Aged | Pyridones - therapeutic use | Cohort Studies | Index Medicus
Journal Article
The American journal of medicine, ISSN 0002-9343, 2017, Volume 130, Issue 9, pp. 1015 - 1023
Abstract Renal impairment increases risk of stroke and systemic embolic events and bleeding in patients with atrial fibrillation. Direct oral anticoagulants... 
Internal Medicine | Atrial fibrillation | Direct oral anticoagulants | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Dabigatran - adverse effects | Pharmaceutical Research - statistics & numerical data | Pyrazoles - therapeutic use | Dabigatran - administration & dosage | Anticoagulants - administration & dosage | Humans | Pharmaceutical Research - standards | Warfarin - adverse effects | Thiazoles - administration & dosage | Antithrombins - administration & dosage | Thiazoles - therapeutic use | Warfarin - administration & dosage | Dabigatran - therapeutic use | Rivaroxaban - administration & dosage | Thiazoles - adverse effects | Factor Xa Inhibitors - administration & dosage | Warfarin - therapeutic use | Pyridones - administration & dosage | Pyridines - adverse effects | Rivaroxaban - adverse effects | Hemorrhage - etiology | Pharmaceutical Research - methods | Renal Insufficiency - complications | Embolism - etiology | Rivaroxaban - therapeutic use | Pyrazoles - adverse effects | Pyridines - therapeutic use | Stroke - prevention & control | Embolism - prevention & control | Pyridines - administration & dosage | Embolism - complications | Risk Assessment | Administration, Oral | Atrial Fibrillation - drug therapy | Antithrombins - therapeutic use | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Factor Xa Inhibitors - therapeutic use | Pyrazoles - administration & dosage | Stroke - etiology | Pyridones - therapeutic use | Pyridones - adverse effects | Therapeutic Equivalency | Stroke (Disease) | Drugstores | Health care industry | Warfarin | Pharmacy | Index Medicus | Abridged Index Medicus
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 03/2012, Volume 107, Issue 3, pp. 584 - 589
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 01/2009, Volume 101, Issue 1, pp. 77 - 85
Dabigatran etexilate has been investigated in three phase III trials for the prevention of venous thromboembolism (VTE). Health technology assessment agencies... 
anticoagulants | thrombosis | prophylaxis | Embolism | Meta-analysis | Anticoagulants | Thrombosis | Prophylaxis | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Venous Thromboembolism - mortality | Anticoagulants - administration & dosage | Arthroplasty, Replacement, Knee - adverse effects | Humans | Dabigatran | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Venous Thromboembolism - prevention & control | Clinical Trials, Phase III as Topic | Enoxaparin - administration & dosage | Pyridines - adverse effects | Benzimidazoles - administration & dosage | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Pyridines - administration & dosage | Drug Administration Schedule | Risk Assessment | Administration, Oral | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Arthroplasty, Replacement, Hip - adverse effects | Venous Thromboembolism - etiology | Hemorrhage - chemically induced | Index Medicus | Administration | Phase III as Topic | Benzimidazoles/administration & dosage/adverse effects/therapeutic use | Pyridines/administration & dosage/adverse effects/therapeutic use | Arthroplasty | Replacement | Oral | Clinical Trials | Kirurgi | Knee/adverse effects | Hemorrhage/chemically induced | Venous Thromboembolism/etiology/mortality/prevention & control | Hip/adverse effects | Anticoagulants/administration & dosage/adverse effects/therapeutic use | Surgery | Enoxaparin/administration & dosage/adverse effects/therapeutic use
Journal Article
Circulation (New York, N.Y.), ISSN 1524-4539, 02/2014, Volume 129, Issue 7, pp. 764 - 772
Dabigatran and warfarin have been compared for the treatment of acute venous thromboembolism (VTE) in a previous trial. We undertook this study to extend those... 
Antagonists & inhibitors | Recurrence | Thrombin | Warfarin | Hemorrhage | Venous thromboembolism | Cardiac & Cardiovascular Systems | Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Anticoagulants - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Warfarin - adverse effects | Male | Antithrombins - administration & dosage | Dabigatran | Heparin - adverse effects | Warfarin - administration & dosage | Venous Thromboembolism - drug therapy | Young Adult | Benzimidazoles - administration & dosage | Adult | Female | Benzimidazoles - adverse effects | Venous Thromboembolism - epidemiology | beta-Alanine - analogs & derivatives | Acute Disease | beta-Alanine - adverse effects | Double-Blind Method | Hemorrhage - epidemiology | Risk Factors | beta-Alanine - administration & dosage | Anticoagulants - adverse effects | Antithrombins - adverse effects | Adolescent | Aged | Hemorrhage - chemically induced | Heparin, Low-Molecular-Weight - administration & dosage | Usage | Care and treatment | Dabigatran etexilate | Thromboembolism | Index Medicus | Abridged Index Medicus | Anticoagulants | Benzimidazoles | Heparin, Low-Molecular-Weight | Life Sciences | Venous Thromboembolism | Antithrombins | Heparin | beta-Alanine
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 08/2012, Volume 60, Issue 8, pp. 738 - 746
Objectives This study sought to perform an indirect comparison analysis of dabigatran etexilate (2 doses), rivaroxaban, and apixaban for their relative... 
Cardiovascular | Internal Medicine | indirect comparisons | dabigatran | atrial fibrillation | rivaroxaban | apixaban | stroke prevention | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | Thiophenes - adverse effects | Humans | Middle Aged | Male | Thiophenes - administration & dosage | Dabigatran | Pyridones - administration & dosage | Rivaroxaban | Clinical Trials, Phase III as Topic | Pyridines - adverse effects | Benzimidazoles - administration & dosage | Female | Benzimidazoles - adverse effects | Odds Ratio | Morpholines - adverse effects | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Pyrazoles - adverse effects | Pyridines - therapeutic use | Stroke - prevention & control | Pyridines - administration & dosage | Administration, Oral | Morpholines - administration & dosage | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Pyrazoles - administration & dosage | Stroke - etiology | Aged | Pyridones - therapeutic use | Hemorrhage - chemically induced | Pyridones - adverse effects | Stroke (Disease) | Usage | Analysis | Atrial fibrillation | Anticoagulants (Medicine) | Universities and colleges | Cardiology | Anticoagulants | Cardiac arrhythmia | Stroke | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article